Latest news with #AlaunosTherapeutics
San Francisco Chronicle
15-05-2025
- Business
- San Francisco Chronicle
Ziopharm: Q1 Earnings Snapshot
HOUSTON (AP) — HOUSTON (AP) — Alaunos Therapeutics, Inc. (TCRT) on Thursday reported a loss of $1.1 million in its first quarter. On a per-share basis, the Houston-based company said it had a loss of 67 cents. The drug developer posted revenue of $2,000 in the period. _____
Yahoo
15-05-2025
- Business
- Yahoo
Ziopharm: Q1 Earnings Snapshot
HOUSTON (AP) — HOUSTON (AP) — Alaunos Therapeutics, Inc. (TCRT) on Thursday reported a loss of $1.1 million in its first quarter. On a per-share basis, the Houston-based company said it had a loss of 67 cents. The drug developer posted revenue of $2,000 in the period. _____ This story was generated by Automated Insights ( using data from Zacks Investment Research. Access a Zacks stock report on TCRT at
Globe and Mail
14-05-2025
- Business
- Globe and Mail
PMGC Capital LLC, a Subsidiary of PMGC Holdings Inc. (Nasdaq: ELAB), To File Schedule 13D Reporting 5.09% Stake in Alaunos Therapeutics, Inc. (Nasdaq: TCRT)
NEWPORT BEACH, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- PMGC Capital LLC ('PMGC Capital,' 'we,' 'our,' or 'us'), a wholly owned subsidiary of PMGC Holdings Inc. (Nasdaq: ELAB), today announced its planned filing of a Schedule 13D with the U.S. Securities and Exchange Commission disclosing beneficial ownership of common stock in Alaunos Therapeutics, Inc. (Nasdaq: TCRT). PMGC Capital has acquired 83,500 shares of Alaunos Therapeutics, representing approximately 5.09% of the company's outstanding shares of common stock, based on Alaunos' Preliminary Schedule 14A filed with the U.S. Securities and Exchange Commission, indicating 1,639,521 shares of common stock outstanding as of May 5, 2025. Alaunos Therapeutics, Inc. ('Alaunos Therapeutics' or 'Alaunos'), headquartered in Houston, Texas, is a clinical-stage oncology-focused cell therapy company. Alaunos is currently exploring strategic alternatives, including but not limited to acquisitions, mergers, reverse mergers, sale of assets, strategic partnerships, capital raises, or other transactions. PMGC Capital believes Alaunos is undervalued and has significant potential to create shareholder value. PMGC Capital intends to engage constructively with Alaunos' management and board of directors to explore strategic opportunities, including potential mergers, acquisitions or partnerships in sectors such as financial technology and cryptocurrency. We commend Alaunos Therapeutics for maintaining a clean capital structure and exercising prudent financial stewardship during challenging market conditions. PMGC Capital looks forward to collaborating with the Alaunos' leadership to pursue initiatives that align with its shared objective of enhancing long-term shareholder value. About PMGC Capital LLC A multi-strategy investment firm focused on direct investments, strategic lending, and acquiring undervalued companies and assets across diverse markets. Our mission is to identify and seize high-potential opportunities, delivering sustainable growth and maximizing returns on capital. About PMGC Holdings Inc. PMGC Holdings Inc. ('PMGC Holdings') is a diversified holding company that manages and grows its portfolio through strategic acquisitions, investments, and development across various industries. Currently, our portfolio consists of three wholly owned subsidiaries: Northstrive Biosciences Inc., PMGC Research Inc., and PMGC Capital LLC. We are committed to exploring opportunities in multiple sectors to maximize growth and value. For more information, please visit Forward-Looking Statements This press release contains forward-looking statements, including statements regarding potential strategic opportunities and the expected benefits thereof. These statements are based on current expectations and involve risks and uncertainties that may cause actual results to differ materially. Therefore, you should not rely on any of these forward-looking statements. These and other risks are described more fully in the Company's filings with the United States Securities and Exchange Commission ('SEC'), including the 'Risk Factors' section of PMGC Holdings' Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 28, 2025, and its other documents subsequently filed with or furnished to the SEC. Investors and security holders are urged to read these documents free of charge on the SEC's web site at All forward-looking statements contained in this press release speak only as of the date on which they were made. Except to the extent required by law, the Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. IR Contact:
Yahoo
04-04-2025
- Business
- Yahoo
Alaunos Therapeutics And 2 Other Promising Penny Stocks To Watch
Amidst a turbulent market backdrop, where major indices like the Dow Jones and Nasdaq Composite have faced significant declines due to escalating trade tensions, investors are increasingly seeking alternative opportunities. Penny stocks, often representing smaller or newer companies, continue to hold allure for those looking beyond traditional large-cap investments. Despite being an older term, they offer potential growth when backed by solid financials; this article explores three such stocks that stand out for their promise and resilience in today's challenging economic landscape. Name Share Price Market Cap Financial Health Rating Safe Bulkers (NYSE:SB) $3.51 $392.12M ★★★★☆☆ Tuya (NYSE:TUYA) $2.79 $1.83B ★★★★★★ Smith Micro Software (NasdaqCM:SMSI) $0.742 $13.53M ★★★★☆☆ Kiora Pharmaceuticals (NasdaqCM:KPRX) $2.8327 $8.43M ★★★★★★ Flexible Solutions International (NYSEAM:FSI) $4.55 $61.59M ★★★★★★ Sensus Healthcare (NasdaqCM:SRTS) $4.90 $82.97M ★★★★★★ TETRA Technologies (NYSE:TTI) $3.02 $458.08M ★★★★☆☆ Imperial Petroleum (NasdaqCM:IMPP) $2.32 $74.01M ★★★★★★ BAB (OTCPK:BABB) $0.76 $5.74M ★★★★★★ CBAK Energy Technology (NasdaqCM:CBAT) $0.727 $68.37M ★★★★★☆ Click here to see the full list of 777 stocks from our US Penny Stocks screener. Here we highlight a subset of our preferred stocks from the screener. Simply Wall St Financial Health Rating: ★★★★☆☆ Overview: Alaunos Therapeutics, Inc. is a clinical-stage company specializing in oncology-focused cell therapies, specifically developing T-cell receptor engineered T-cell therapies to address various solid tumors, with a market cap of $4.48 million. Operations: Alaunos Therapeutics, Inc. does not report any revenue segments as it is a clinical-stage company focused on developing cell therapies for oncology applications. Market Cap: $4.48M Alaunos Therapeutics, Inc., a clinical-stage biotech company, remains pre-revenue with sales of US$0.01 million for 2024 and a net loss of US$4.68 million, showing an improvement from the previous year's larger loss. Despite having no debt and sufficient short-term assets to cover liabilities, the company faces challenges with less than one year of cash runway and high volatility in its share price. The board is considered experienced with an average tenure of 4.3 years, but the management team's experience level is unclear due to insufficient data. Shareholder dilution has not been significant recently. Navigate through the intricacies of Alaunos Therapeutics with our comprehensive balance sheet health report here. Understand Alaunos Therapeutics' track record by examining our performance history report. Simply Wall St Financial Health Rating: ★★★★☆☆ Overview: loanDepot, Inc. operates in the United States by originating, financing, selling, and servicing residential mortgage loans and has a market cap of approximately $394.07 million. Operations: The company's revenue primarily comes from originating, financing, and selling mortgage loans, generating $985.65 million. Market Cap: $394.07M loanDepot faces challenges with high net debt to equity at 961.6% and ongoing unprofitability, reporting a net loss of US$33.23 million for Q4 2024. Despite this, the company maintains strong short-term assets exceeding its liabilities and has not significantly diluted shareholders recently. Leadership changes are underway with founder Anthony Hsieh returning as Executive Chairman, while a CEO search is conducted. Strategic moves include expanding the equityFREEDOM portfolio and forming joint ventures like Onx X+ Mortgage to enhance market presence in Florida and Texas, potentially capitalizing on new revenue opportunities amidst industry volatility. Get an in-depth perspective on loanDepot's performance by reading our balance sheet health report here. Evaluate loanDepot's prospects by accessing our earnings growth report. Simply Wall St Financial Health Rating: ★★★★★★ Overview: Vaso Corporation, with a market cap of $25.05 million, operates in the healthcare equipment and information technology industries both in the United States and internationally. Operations: There are no reported revenue segments for Vaso Corporation. Market Cap: $25.05M Vaso Corporation, with a market cap of US$25.05 million, operates debt-free and has seen a reduction in its debt levels from five years ago. Despite experiencing negative earnings growth of -80.2% over the past year, Vaso remains profitable with sales reaching US$86.77 million for 2024, though net income declined to US$0.951 million from the previous year's US$4.81 million. The company's short-term assets significantly exceed both short and long-term liabilities, offering financial stability amidst fluctuating profit margins and low return on equity at 3.4%. Recent board changes include Edgar Rios becoming Vice Chairman while retaining his audit committee role. Dive into the specifics of Vaso here with our thorough balance sheet health report. Review our historical performance report to gain insights into Vaso's track record. Dive into all 777 of the US Penny Stocks we have identified here. Seeking Other Investments? These 11 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NasdaqCM:TCRT NYSE:LDI and OTCPK:VASO. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Sign in to access your portfolio
